Lupin and Axantia enter into agreement for Pegfilgrastim in the Middle East and North Africa

Global pharma major, Lupin Limited (Lupin) announced today that they have entered into a License, Supply and Technology Sharing agreement with Axantia Holding (Axantia), a leading pharmaceutical company in the region operating through its pharmaceutical subsidiaries; Pharma International Company and Med City Pharmaceutical Industries. Under the terms of Agreement, Axantia will register, distribute and market biosimilar Pegfilgrastim Drug Product in certain territories including Saudi Arabia, certain GCC countries, Jordan, Lebanon, Iraq, Sudan, Libya and Algeria.

Lupin had earlier received the U.S. FDA acceptance for review of the Biologics License Application (BLA) for its proposed biosimilar to Neulasta® (pegfilgrastim) through a filing using the 351(k) pathway.

Pegfilgrastim is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherapy.

Shares of Lupin Limited was last trading in BSE at Rs. 908.35 as compared to the previous close of Rs. 899.90. The total number of shares traded during the day was 38189 in over 2482 trades.

The stock hit an intraday high of Rs. 914.60 and intraday low of 896.15. The net turnover during the day was Rs. 34589322.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Agreement AxantiaHolding Biosimilar